

Claims:

1. An orally deliverable pharmaceutical composition comprising an effective amount of 2'-deoxy-2'-(fluoromethylene)cytidine for treating a neoplastic disease or viral disease in a mammal wherein said composition is encapsulated in a material which is selected to be dissolution resistant at a pH of about 4 to 5 or less and to readily dissolve at a pH of greater than about 4 to 5.
2. The orally deliverable pharmaceutical composition according to Claim 1 further comprising a pharmaceutically acceptable excipient or excipients.
3. The orally deliverable pharmaceutical composition according to Claim 2 wherein the pharmaceutically acceptable excipient or excipients comprise only the encapsulation material.
4. The orally deliverable pharmaceutical composition according to Claim 2 wherein a separate pharmaceutically acceptable excipient or excipients is/are included in the encapsulation material.
- 15 5. The orally deliverable pharmaceutical composition according to any of Claims 1, 2, 3 or 4 wherein the encapsulation material is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, poly(vinyl acetate phthalate), hydroxypropyl methylcellulose acetate succinates, poly(meth)acrylates and cellulose acetate phthalate/diethylphthalate.
- 20 6. The orally deliverable pharmaceutical composition according to Claim 5 wherein the encapsulation material is selected from the group consisting of a copolymers of methacrylic acid and acrylic acid esters and copolymers of methacrylic acid and methacrylic acid esters.

7. The orally deliverable pharmaceutical composition according to Claim 1 wherein the composition comprises from about 50 to about 99.5 weight percent of the pharmaceutically acceptable excipient(s) and from about 0.5 to about 50 weight percent of 2'-deoxy-2'-(fluoromethylene)cytidine.

5 8. A method for enhancing the oral bioavailability of 2'-deoxy-2'-(fluoromethylene)cytidine when orally delivered to a mammal which method comprises:

(a) encapsulating 2'-deoxy-2'-(fluoromethylene)cytidine in a pharmaceutically acceptable material which is selected to be dissolution resistant at 10 a pH of 4 to 5 or less and to readily dissolve at a pH of greater than 4 to 5; and

(b) orally delivering the product prepared in (a) above to said mammal.